Skip to main content
. 2022 Apr 13;14(8):1949. doi: 10.3390/cancers14081949

Table 4.

Disease-free survival (DFS) and overall survival (OS) in early-stage NSCLC with PDL-1 expression.

Study Year Kind of Study Patients Cut-Off Stage DFS OS
Cooper et al. 2015 Retrospective 678 ≥50% I–III n.r. 1 positive
Shi et al. 2021 Retrospective 3790 variable I–III negative negative
D’Arcangelo et al. 2019 Retrospective 289 ≥50% I–III n.s. n.s.
Sum JM et al. 2016 Retrospective 520 1–95%/≥96% I–III negative n.s.

1 n.r.: not reported. n.s.: not significant.